Warning: fopen(/home/virtual/epih/journal/upload/ip_log/ip_log_2025-05.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96 Risk of new-onset seizures following immunization against COVID-19: a self-controlled case-series study
Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > Epidemiol Health > Accepted Articles > Article
Original article Risk of new-onset seizures following immunization against COVID-19: a self-controlled case-series study
Hwa Yeon Ko1orcid , Dongwon Yoon1,2orcid , Ju Hwan Kim1,2orcid , Han Eol Jeong1,2orcid , Seung Bong Hong3,4orcid , Won Chul Shin6orcid , JU YOUNG SHIN4,6orcid
Epidemiol Health 2025;e2025024
DOI: https://doi.org/10.4178/epih.e2025024 [Accepted]
Published online: May 2, 2025
1Sungkyunkwan University, School of Pharmacy, Suwon, Gyeong gi-do, Korea
2Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea
3Department of Neurology, Samsung Medical Center, Seoul, Korea
4SungKyunKwan University, School of Medicine, Suwon, Gyeong gi-do, Korea
5Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Korea
6Department of Neurology, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea
Corresponding author:  Won Chul Shin,
Email: shin.jy@skku.edu
JU YOUNG SHIN,
Email: shin.jy@skku.edu
Received: 16 April 2024   • Revised: 16 April 2025   • Accepted: 23 April 2025
  • 346 Views
  • 19 Download
  • 0 Crossref
  • 0 Scopus
Full Article

Download PDF Download PDF

Abstract

OBJECTIVES
Despite emerging reports of new-onset seizures (NOS) following COVID-19 vaccination, safety evidence regarding the risk of NOS after vaccination remains limited. We aimed to investigate the potential association between NOS and COVID-19 vaccination.
METHODS
We conducted a self-controlled case series study utilizing a nationwide database linking the COVID-19 vaccination registry and the National Health Information Database (from February 2021 to October 2022). We identified adults (≥18 years) who received COVID-19 vaccination (BNT162b2, ChAdOx1 nCoV-19, mRNA-1273, NVX-CoV2373, or Ad26.COV2.S) and had a diagnosis of NOS accompanied by prescriptions of anti-seizure drugs. The observation period was defined as 240 days following vaccination. We evaluated the risk of NOS during a risk window of 28 days after vaccination compared to the control window (the remaining observation period excluding the risk window). Incidence rate ratios (IRRs) with 95% confidence intervals (CIs) were estimated using a conditional Poisson regression model.
RESULTS
Among 42,155,198 COVID-19 vaccine recipients, we identified 1,849 and 4,217 patients with NOS in the risk and control windows, respectively. There was no increased risk of NOS within the 28-day period following vaccination (IRR, 0.99; 95% CI, 0.94–1.05). Although results from subgroup analyses by vaccine type were largely consistent with the main findings (IRR, 0.95; 95% CI, 0.88–1.03 for BNT162b2; IRR, 0.95; 95% CI, 0.77–1.16 for ChAdOx1 nCoV-19; IRR, 1.58; 95% CI, 0.52–4.83 for Ad26.COV2.S), a marginally elevated risk was observed for mRNA-1273 (IRR, 1.21; 95% CI, 1.04–1.42).
CONCLUSIONS
There was no evidence of an increased risk of NOS following COVID-19 vaccination. These findings can be used as safety evidence in clinical decision-making and to bolster public confidence in COVID-19 vaccines. 

Related articles
Epidemiol Health : Epidemiology and Health
© Korean Society of Epidemiology.
TOP